Table 2 The summary and comparison of PROTACs targeting EGFR
From: PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)
No. | PROTAC | Warhead | E3 ligase |
|---|---|---|---|
1 | MS39(22) | Gefitinib | VHL |
2 | MS154(23) | Gefitinib | CRBN |
3 | 24 | Osimertinib | CRBN |
4 | 25 | Gefitinib | VHL |
5 | 26 | Pyrido[3,4-d] pyrimidine moiety | CRBN |
6 | 27 | Pyrido[3,4-d] pyrimidine moiety | VHL |
7 | P3(28) | Purine-containing derivative | VHL |
8 | 29 | XTF-262 | VHL |
9 | SIAI125(30) | Canertinib | CRBN |
10 | SIAI126(31) | Canertinib | CRBN |
